Drug Profile
MEDI 8111
Alternative Names: Rh-Factor II; rhFIILatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Antithrombotics; Enzyme precursors
- Mechanism of Action Blood coagulation factor replacements; Prothrombin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haemorrhage
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Haemorrhage(In volunteers) in United Kingdom (IV, Infusion)
- 01 Oct 2014 AstraZeneca (MedImmune) completes a phase I trial in Haemorrhage (In volunteers) in United Kingdom (NCT01958645)
- 22 Nov 2013 Phase-I clinical trials in Haemorrhage (In volunteers) in United Kingdom (IV)